VOLUME 11 - NUMBER 3

CNS SPECTRUMS®

INTRODUCTION

"Mirror, Mirror..." Whose Explanation is the Fairest? Evolving Notions of Somatization and Idiopathic Physical Symptoms

C.C. Engel

REVIEW ARTICLES

The Potentially Somatizing Effect of Clinical Consultation

P. Salmon

Idiopathic Physical Symptoms:

A Common Manifestation of Psychiatric Disorders in Primary Care

J.I. Escobar, A. Interian, A. Díaz-Martínez, and M. Gara

Antidepressants and Cognitive-Behavioral Therapy for Symptom Syndromes

J.L. Jackson, P.G. O'Malley, and K. Kroenke

Explanatory and Pragmatic Perspectives Regarding Idiopathic Physical Symptoms and Related Syndromes

C.C. Engel

ORIGINAL RESEARCH

A Discrimination Based on Autogenous Versus Reactive Obsessions in Obsessive-Compulsive Disorder and Related Clinical Manifestations

L. Besiroglu, M.Y. Agargun, O. Ozbebit, and A. Aydin

CASE REPORT

Pramipexole: Augmentation in the Treatment of Depressive Symptoms

S. Gupta, J.L. Vincent, and B. Frank

Index Medicus/MEDLINE citation: CNS Spectr

www.cnsspectrums.com

Because he's in demand all day long...

Aim Higher With ADDERALL XR®

The most common adverse events in clinical studies of ADDERALL XR included: *pediatric*-loss of appetite, insomnia, abdominal pain, and emotional lability; adolescent-loss of appetite, insomnia, abdominal pain, and weight loss; adult-dry mouth, loss of appetite, insomnia, headache, and weight loss.

The effectiveness of ADDERALL XR for long-term use has not been systematically evaluated in controlled trials. As with other psychostimulants indicated for ADHD, there is a potential for exacerbating motor and phonic tics and Tourette's syndrome. A side effect seen with the amphetamine class is psychosis. Caution also should be exercised in patients with a history of psychosis.

Abuse of amphetamines may lead to dependence. Misuse of amphetamines may cause sudden death and serious cardiovascular adverse events. These events have also been reported rarely with amphetamine use. ADDERALL XR generally should not be used in those with structural cardiac abnormalities. ADDERALL XR is contraindicated in patients with symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism and glaucoma, known hypersensitivity to this class of compounds, Agitated states, history of drug abuse, or current or recent use of MAO inhibitors. ADDERALL XR should be prescribed with close physician supervision.

Please see references and brief summary of prescribing information on adjacent page.

A|138

10/05

IMS Dataview, July 2005

Prescribed

Brand of ADULT ADHD Medication

www.ADDERALLXR.com www.ADHDSupport.com


Shire US Inc. ...your ADHD support company 1-800-828-2088

©2005 Shire US Inc., Wayne, Pennsylvania 19087

V() RK

For Efficacy That Measures Up to Life's Demands

- Once-daily dosing provides all-day symptom control'
- Mean ADHD-RS total scores for adults receiving ADDERALL XR 20 mg decreased by 41%²
- Clinical data in adults demonstrate that ADDERALL XR is generally well tolerated³
- Extended-release formulation may increase the potential for compliance⁴



Reach new heights

References: 1. Faraone SV, Biederman J. A controlled study of functional impairments in 500 ADHD adults. Presented at: 157th Annual Meeting of the American Psychiatric Association; May 5, 2004; New York, NY. 2. Data on file, Shire US Inc., 2005. 3. ADDERALL XR[®] [package insert], Shire US Inc., 2005. 4. Claxton AJ, Cramer J, Pierce C. A systematic review of the association between dose regimens and medication compliance. *Clin Ther*. 2001;23:1296-1310.

BRIEF SUMMARY: Consult the full prescribing information for complete product information.

ADDERALL X8° CAPSULES

CII Bx Only

AMPHETAMINES HAVE A HIGH POTENTIAL FOR ABUSE. ADMINISTRATION OF AMPHETAMINES FOR PROLONGED PERIODS OF TIME MAY LEAD TO ORUG DEPENDENCE. PARTICULAR ATTENTION SHOULD BE PAID TO THE POSSIBILITY OF SUBJECTS OBTAINING AMPHETAMINES FOR NON-THERAPEUTIC USE OR DISTRIBUTION TO OTHERS AND THE DRUGS SHOULD BE PRESCRIBED OR DISPENSED SPANINGLY.

MISUSE OF AMPHETAMINE MAY CAUSE SUDDEN DEATH AND SERIOUS CARDIOVASCULAR ADVERSE EVENTS.

INDICATIONS ADDERALL XRe is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The efficacy of ADDERALL XRe in the treatment of ADHD was established on the basis of two controlled trials in children aged 6 to 12. one controlled trial in adolescents aged 13 to 17, and one controlled trial in adults who met DSM-IV* critera tor ADHD, along with extrapolation from the known efficacy of ADDERALL*, the immediate-release formulation of this substance. CONTRAINDICATIONS

CONTRAINDICATIONS Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncrasy to the sympathomimetic amines, glaucoma. Apitatel states. Patients with a history of drug abuse. During or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crises may result).

(hyperfensive crises may result): WARNINGS Psychosis: Clinical experience suggests that, in psychotic patients, administration of ampletamine may exacerbate symptoms of behavior disturbance and thought disords. Long-Term Suppression of Growth: Data are indequate to determine whether chronic use of stimulants in children, including ampletamine, may be causally associated with suppression of growth. Therefore, growth isolud be monitored during treatment, and patients who are not. Sudden Destin and Pre-existing Structural Cardiac Abnormalities: Sudden test has been reported in association with ampletamine treatment at usual doses in children, with structural cardiac abnormalities. Adderall XRe generally should not be used in children, aooescents, or aoutts with structural cardiac abnormalities.

Subcluin a consist service management of the service of the servic

structural cardiac abnormalities. Adderall XH[®] generally should not be used in Children, adorescents, or aduuts with structural cardiac abnormalities. **PRECAUTIONS General:** The least amount of amphetamine feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage. **Hypertension:** Caution is to be exercised in prescribing amphetamines for patients with even mild hypertension (see CONTRAINDICATIONS). Blood pressure should be treated with dose reduction and/or appropriate metrication. Sustained increases in blood pressure should be treated with dose reduction and/or appropriate metrication. In a controlled 4-week outgratient clinical study of addicescents with ADHD, isolated systolic blood pressure elevations ≥15 mmHg were observed in 7/64 (11%) placebo-treated patients and 7/100 (7%) patients receiving ADDERALL XR = 10 or 20 mg. Isolated elevations in disolic blood pressure 2 8 mmHg were observed in 16/64 (25%) placebo-treated patients and 22/100 (22%) ADDERALL XR=10 received a 2000 pressure. Al ADDERALL XR=, respectively, Higher single doses were associated with agreater increase in systolic blood pressure. (Above the upper 95% Cl for age, gender and stature) were observed in 217 (12%) and 8/23 (35%), subjects administered 10 mg and 20 mg ADDERALL XR=, respectively, Higher single doses were associated with agreater increase in systolic blood pressure. All increases were transient, appeared maximal at 2 to 4 hours post dose and not associated with symptomes. **Ties:** Amphetamines have been associated with decreased appetite. Absolute weight attenues have encytoted to exacorbate motior and phonic loss and not associated with symptomes. **Ties:** Amphetamines have been associated with decreased appetite. Absolute weight attenues weight change the absolute weight attenues and are greatest in the heaviest of the administer sectiving 10 mg and 20 mg ADERALL XR= Higher doses were associated with greater weight loss with the initial 4 weeks of therapy wass

Metheramine therapy—Unitary excretion or ampletamines is involved, see an exception of phenobarbital in metheramine therapy. Norepinephrine—Amphetamines enhance the adrenergic effect of norepinephrine. Phenobarbital—Amphetamines may delay intestinal absorption of phenobarbital; co-administration of phenobarbital may produce a synergistic anticonvulsant action. Phenytoin—Amphetamines may delay intestinal absorption of phenytoin; co-administration of phenytoin may produce a syn-

Phenobarbital—Amphetamines may delay intestinal absorption of phenobarbital; co-administration of phenobarbital may produce a synergistic anticonvulsant action. Proprojecies asynonychene—In cases of propoxybnee overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur. Veraturun atkindos—Amphetamines may intestinal absorption of phenytoin; co-administration of phenytoin may produce a syn-ergistic anticodes—Amphetamines inhibit the hypotensive effect of veraturun atkindos. Drug/Laboratory Test Interactions: Amphetamines can cause a significant elevation in plasma corticosteroid levels. This increase is greates in the evening. Amphetamines may interfere with uninary steroid determinations. Carcinogenesis/Mutagenesis and Impairment of Forlitty: No evidence of carcinogencity was found in studies in which d.I-amphetamine (enantiomer ratio of 1:1) was administered to mice and rats in the diet for 2 years at doses of up to 30 mg/kg/day in male mice, 19 mg/kg/day in female mice, and 5 mg/kg/day in male and female rats. These doses are approximately 2.4, 1.5, and 0.8 times, respectively, the maximum recommended human dose of 30 mg/kg/day (bat) on amg/m² body surface area basis. Amphetamine, in the enantiomer ratio present in ADDEFALL^e (immediate-release) (d- to 1 - ratio of 3.1), was not clastogenic in the mouse bone marrow micronucleus test, and equivce area ponses in the Amse test, and thequive responses in the mouse bone mar-row micronucleus test, an equivccal response in the Amse test, and nequive responses in the in witro sister chromatud exchange and chromosomal aberration assays. Amphetamine, in the enantiomer ratio present in ADDEFALL^e (immediate-release) (d- to 1 - ratio of 3.1), did not adversely affect fertility or early embryonic development in the rat at doses of up to 20 mg/kg/day (approximately 2.5 times the maximum recommended human dose of 30 mg/day on a mg/m² body surface area basis. Progmary: Pregnancy Category C. Amphetamine, in t

Usage in rousing mouses, composition of the second second

Generative Use: ADDEHALL XM^e has not been studied in the genaric population. **ADVERSE EVENTS** The premarketing development program for ADDERALL XM^e included exposures in a total of 1315 participants in clinical trials (635 pediatric patients, 350 addoscent patients, 246 adult patients, 82 heathy adult subjects). Of these, 635 patients (ages 6 to 12) were evaluated in two controlled clinical studies, one open-label clinical study, and two single-dose clinical paramacology studies (N=40). Safety data on all patients are included in the discussion that follows. Adverse eractions were assessed by collecting adverse events, results of physical examinations, vital signs, weights, laboratory analyses, and ECGs. Adverse events during exposure were obtained primarily by general inquiry and recorded by clinical investigators using terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of

individuals experiencing adverse events without first grouping similar types of events into a smaller number of standardized event categories. In the tables and listings that follow, COSTART terminology has been used to classify reported adverse events. The stated frequencies of adverse events represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse event of the type listed. **Adverse event sasociated with discontinuation of treatment**: In two placebo-controlled studies of up to 5 weaks duration among children with AdVerse vertiles are events of ADDERALL XR* treated patients discontinued due to adverse events (including 3 patients with loss of appetite, one of whom also reported insomnia) compared to 2.7% (7/258) receiving placebo. The most frequent adverse events associated with discontinuation of ADDERALL XR* treated patients discontinued due to adverse events (including 3 patients with loss of appetite, one of whom also reported insomnia) compared to 2.7% (7/258) receiving placebo. The most frequent adverse events associated with discontinuation of ADDERALL XR* and the set of the proving the patients (N=595) are presented below. Over half of these patients were exposed to ADDERAL XR* for 12 months or more. Adverse event Anorexia (loss of appetite) 2.9

ADDEFALL XRe for 12 months or more: Adverse event Anorexia (loss of appetite) Insomnia Morexia (loss of appetite) Insomnia Morexia (loss of appetite) Insomnia Morexia (loss of appetite) In a separate placebo-controlled 4-week study in adolescents with ADHD, eight patients (14-233). Three patients discontinued due to insomnia and one patient each for depression, motor tics. Needaches, light-headethess, and anxety In a separate placebo-controlled 4-week study and patients (14-233). Three patients discontinued due to insomnia and one patient each for depression, motor tics. Needaches, light-headethess, and anxety In one placebo-controlled 4-week study and guilts with ADHD, patients who discontinued In a separate placebo-controlled 4-week study and patients (14-233). Three patients who discontinued insomnia and one patient each for depression, motor tics. Needaches, light-headethess, and anxety In a lone placebo-controlled 4-week study and guilts with ADHD, patients who discontinued Ireatment due to adverse events among ADDEFALL XR+-treated patients (N-13) were 3.1% Ino, hest patient, coccaine crawing leverad bloch pressure, and weight loss. Adverse events reported in 14 adverse events reported in 14 and oblescents and adults, respectively, treated with ADDEFALL XR+ or placebo are presented in the tables blow. The prescriber should be aware that thes figures, however, do provide the prescribing adverse events in the course of usual medical practice where patient characteristics and other incates in the population studied. The toro more should be start of the deprescients on adautis. The of the depression in the stable show. The prescriber should be aware that these figures, however, do provide the prescribing and the compared with figures obtained from other clinical investigations involving different the table be a 56 deference of the stable. The prescriber has a 56 deference of the stable. The prescriber has a 56 deference of the stable. The one prescriber has 56 deference of the st

bour of the second		(n=374)	(n=210)
General	Abdominal Pain (stomachache)	14%	10%
	Accidental Injury	3%	2%
	Asthenia (fatíque)	2%	0%
	Fever	5%	2%
	Infection	4%	2%
	Viral Infection	2%	0%
Digestive	Loss of Appetite	22%	2%
System	Diarrhea	2%	1%
	Dyspepsia	2%	1%
	Nausea	5%	3%
	Vomiting	7%	4%
Nervous System	Dizziness	2%	0%
	Emotional Lability	9%	2%
	Insomnia	17%	2%
	Nervousness	6%	2%
Metabolic/Nutritional	Weight Loss	4%	0%

Body System	Preferred Term	ADDERALL XR* (n=233)	Placebo (n=54)
General	Abdominal Pain (stomachache)	11%	2%
Digestive System	Loss of Appetite ^b	36%	2%
Nervous System	Insomnia *	12%	4%
	Nervousness	6%	6%*
Metabolic/Nutritional	Weight Loss *	9%	0%

Appears the same due to rounding
¹ Dos-related adverse events
Note: The following events did not meet the criterion for inclusion in Table 2 but were reported by 2% to 4% of adolescent
patients receiving ADDERALL XR with a higher incidence than patients receiving placebo in this study: accidental injury,
asthenia (tatigue, dry mouth, dyspepsia, emotional lability, nausea, somnolence, and vomiting.
¹Included doese up to 40 mg

Table 3 Adverse Events Reported by 5% or More of Adults Receiving ADDERALL XR® with Higher incidence Than on Placebo in a 255 Patlent Clinical Forced Weekly-Dose Titration Study*_____

Body System	Preferred Term	ADDERALL XR* (n=191)	Placebo (n⇒64)
General	Asthenia Headache	6% 26%	5% 13%
Digestive System	Loss of Appetite Diarrhea Dry Mouth Nausea	33% 6% 35% 8%	3% 0% 5% 3%
Nervous System	Agitation Anxiety Dizziness Insomnia	8% 8% 7% 27%	5% 5% 0% 13%
Cardiovascular System	Tachycardia	6%	3%
Metabolic/Nutritional	Weight Loss	11%	0%
Urogenital System	Urinary Tract Infection	5%	0%

Note: The following events did not meet the criterion for inclusion in Table 3 but were reported by 2% to 4% of adult patients receiving ADDERALL XR[®] with a higher incidence than patients receiving placebo in this study: infection, photoesnitivity reaction, constipation, tooth disorder, emotional lability, libido decreased, somnolence, speech disorder, palpitation, whiching, dyspens, sweating, dysmenorrhea, and impotence.

Included does up to 60 mg. The following adverse reactions have been associated with amphetamine use: Cardiovascular Palpitations. Eachycardia, elevation of blood pressure, sudden dath, myocardial infarction. There have been isolated reports of cardiomyopathy associated with chronic amphetamine use: Cardiovascular Palpitations. Eachycardia, elevation of blood pressure, sudden dath, myocardial infarction. There have been isolated reports of cardiomyopathy associated with chronic amphetamine use. Central Nervous System: Byochitic episodes at recommended doses, overstimulation, restlessness, dizziness, insomnia, euphoria, dyskinesia, dysphoria, depression, tremor, headache, exacerbation of motor and phonic tics and Tourette's syndrome, sizures, stroke. Gastrointestinal: Dryness of the mouth, unpleasant taste, diarrhea, constipation, other gastrointestinal disturbances. Anorexia and weight loss may occur as undesirable effects. Allergic: Urticaria. Endocrine: Impetence, changes in libido. **DRUG ABUSE AND DEPENDENCE** ADDEFALL XHP is a Schedul II controlled substance. Amphetamines have been extensively abused. Tolerance, extreme psychological dependence, and severe social disability have occurred. There are reports of chardin instration results in extreme fatigue and mental depression; changes are also noted on following prolonged high dosage administration results in extreme tangue and mental depression; changes are also noted on following prolonged high dosage administration results in extreme tangue and mental depression; changes are also noted on following prolonged high dosage administration results in extreme tangue and mental depression; changes are also noted on following prolonged high dosage administration results in extreme tangue and mental depression; changes are also noted on folically indistrustion uschizophrene. **OVENDOSAGE** Individual patient response to amphetamines varies widely. Toxic symptoms may occur dilosyncratically at low doses.

elinicativ indistinguishable from schizophrenia. **OVERDOSAE** Individual patient response to ampletamines varies widely. Toxic symptoms may occur idiosyncratically at low doess. Symptoms: Manifestations of acute overdosage with ampletamines include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, panic states, hyperpyrexia and rhabdomyolysis. Fatigue and depression sysally follow the central nervous system stimulation. Carciovascular effects include arthythmias, hypertension ar hypertension and circulatory collapse. Eastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps. Fatal poisoning is usually preded by convulsions and come advision and circulatory collapse. Eastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps. Fatal poisoning is usually preded by convulsions and come advision. Experimer with hemodiaysis or peritoreal dialysis is inadequate to permit recommendation in this regard, actidification or the urine increase ampletamine eventions, but is believed to increase nsk of acute erral failuris in myodiobinuria is present. It acute seviet hypertension complicates ampletamine overlosage, atministration of intravenous phenolohimine has been suggested. However, a gradual drop in blood pressure will usually result when sufficient sadation has been clineved. Chlorpronazine alight ight-resistant container as defined in the USP. Store at 25° C (T7° F). Excursions permitted to 15·30° C 16/9489 F) less USP Somtole Hoom Temperature. Weak addistion. MDERALLE sand bord persure registered in the USP store at 25° C (T7° F). Excursions permitted to 15·30° C 16/9489 F) less USP Somtole Hoom Temperature. Weak addistion. MDERALLE sand bord persure registered in the USP store at 25° C (T7° F). Excursions permitted to 15·30° C 16/9489 F) less USP Somtole Hoom Temperature. Weak addistion. 01766 3810107 006 Rev. 805 ABFS

381 0107 006 Rev. 8/05 ABFS8





5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg CAPSULES (Mixed Salts of a Single-Entity Amphetamine Product) Dextroamphetamine Sultate Dextroamphetamine Saccharate Amphetamine Aspartate Monohydrate Amphetamine Sulfate

Body System	Preferred Term	ADDERALL XR® (n=374)	Placebo (n=210)
General	Abdominal Pain (stomachache)	14%	10%
	Accidental Injury	3%	2%
	Asthenia (fatíque)	2%	0%
	Fever	5%	2%
	Infection	4%	2%
	Viral Infection	2%	0%
Digestive	Loss of Appetite	22%	2%
Syštem	Diarrhea	2%	1%
	Dyspepsia	2%	1%
	Nausea	5%	3%
	Vomiting	7%	4%
		0.4/	

Table 2 Adv arse Events Reported by 5% or more of Adolescents Weighing < 75 kg/165 lbs Receiving ADDER≜I I_XR≉ with

Higher Incidence Than Placebo in a 287 Patient Clinical Forced Weekly-Dose Titration Study*			
Body System	Preferred Term	ADDERALL XR* (n=233)	Placebo (n=54)
General	Abdominal Pain (stomachache)	11%	2%
Digestive System	Loss of Appetite ^b	36%	2%
Nervous System	Insomnia *	12%	4%

EDITORS

EDITOR

Jack M. Gorman, MD Harvard Medical School Boston, MA

ASSOCIATE AND FOUNDING EDITOR Eric Hollander, MD

Mount Sinai School of Medicine New York, NY

INTERNATIONAL EDITOR Joseph Zohar, MD Chaim Sheba Medical Center Tel-Hashomer, Israel

ASSOCIATE INTERNATIONAL EDITORS EUROPE

Donatella Marazziti, MD University of Pisa Pisa, Italy

MID-ATLANTIC Dan J. Stein, MD, PhD University of Cape Town Cape Town, South Africa

FAR EAST Shigeto Yamawaki, MD, PhD Hiroshima University School of Medicine Hiroshima, Japan

CONTRIBUTING WRITERS

Lutfullah Besiroglu, MD Charles C. Engel, MD, MPH Javier I. Escobar, MD Sanjay Gupta, MD Jeffrey L. Jackson, MD, MPH Peter Salmon, DPhil

COLUMNIST Dan J. Stein, MD, PhD

MEDICAL REVIEWER David L. Ginsberg, MD

CME COURSE DIRECTOR Eric Hollander, MD

SUPPLEMENT EDITORS Eric Hollander, MD Joseph Zohar, MD

PUBLICATION STAFF

CEO & PUBLISHER Darren L. Brodeur

ASSOCIATE PUBLISHER Elizabeth Katz

MANAGING EDITOR Christopher Naccari

SENIOR EDITOR Deborah Hughes

SALES & MARKETING ASSOCIATE Jennifer Gomez

DEPUTY SENIOR EDITOR José R. Ralat

NEUROLOGISTS

Mitchell F. Brin, MD University of California, Irvine Irvine, CÁ

Jeffrey L. Cummings, MD University of California, Los Angeles Los Angeles, CA

EDITORIAL ADVISORY BOARD

Jerome Engel, Jr., MD, PhD University of California, Los Angeles Los Angeles, CA

Mark S. George, MD Medical University of South Carolina Charleston, SC

Deborah Hirtz, MD National Institute of Neurological Disorders and Stroke, NIH Rockville, MD

Richard B. Lipton, MD Albert Einstein College of Medicine Bronx, NY

C. Warren Olanow, MD, FRCPC Mount Sinai School of Medicine New York, NY

Steven George Pavlakis, MD Maimonides Medical Center Brooklyn, NY

Stephen D. Silberstein, MD, FACP Thomas Jefferson University Philadelphia, PA

Michael Trimble, MD, FRCP, FRPsych National Hospital for Neurology and Neurosurgery London, United Kingdom

PSYCHIATRISTS Margaret Altemus, MD Cornell University Medical College New York, NY

Dennis S. Charney, MD Mount Sinai School of Medicine New York, NY

Dwight L. Evans, MD University of Pennsylvania Philadelphia, PA

Siegfried Kasper, MD University of Vienna Vienna, Austria Martin B. Keller, MD Brown Medical School Providence, RI

Lorrin M. Koran, MD Stanford University School of Medicine Stanford, CA Yves Lecrubier, MD

Hôpital de la Salpêtrière Paris, France

Herbert Y. Meltzer, MD Vanderbilt University Medical Center Nashville, TN

Stuart A. Montgomery, MD St. Mary's Hospital Medical School London, United Kingdom

Charles B. Nemeroff, MD, PhD Emory University School of Medicine Atlanta, GA

Humberto Nicolini, MD, PhD National Mexican Institute of Psychiatry Mexico City, Mexico Stefano Pallanti, MD, PhD

University of Florence Florence, Italy

Katharine Phillips, MD Brown Medical School Providence, RI

Harold A. Pincus, MD Western Psychiatric Institute & Clinic RAND-University of Pittsburgh Health Institute, Pittsburgh, PA Scott L. Rauch, MD

Massachusetts General Hospital Charlestown, MA

Alan F. Schatzberg, MD Stanford University School of Medicine Stanford, CA

Thomas E. Schlaepfer, MD University of Bonn Bonn, Germany

Stephen M. Stahl, MD, PhD University of California, San Diego La Jolla, CA

Norman Sussman, MD, DFAPA New York University Medical School New York, NY

Karen Dineen Wagner, MD, PhD The University of Texas Medical Branch Galveston, Texas

Herman G.M. Westenberg, MD University Hospital Utrecht Utrecht, The Netherlands Stuart C. Yudofsky, MD Baylor College of Medicine Houston, TX

ART DIRECTOR Derek Oscarson

GRAPHIC DESIGNER Michael J. Vodilko

CONTROLLER John Spano

OFFICE MANAGER Manuel Pavón

INFORMATION TECHNOLOGY Clint Bagwell Consulting

CORPORATION COUNSEL Lawrence Ross, Esq. Bressler, Amery, and Ross

CNS SPECTRUMS The International Journal of Neuropsychiatric MediPsychiatry Weekly.

CNS Spectr

PRIMARY PSYCHIATRY

156

March 2006

ASSOCIATE EDITOR-ENDURING MATERIALS Shelley Wong

ASSOCIATE EDITORS Peter Cook Dena Croog

ACQUISITIONS EDITORS

COPY EDITOR Keith Papa

Lisa Arrington Shoshana Bauminger

INTERN Stephanie Spano

Publishers of



Neuropsychopharmacology in the Millennium



The CINP2006 scientific program registration, accommodations and travel information are available on-line at

www.CINP2006.com

Call (1) 615-322-2006 for questions and further information. The CINP is coming to the U.S. for the first time in a decade, bringing with it the best in clinical, translational and basic research concerning mental illness and neuroscience. The scientific program includes nearly 100 symposia and satellite sessions on addiction, affective disorders, anxiety disorders, dementias, schizophrenia and psychosis as well as translational research and basic neuroscience. In addition, there will be Meet the Expert sessions, workshops and literally hundreds of posters presented by researchers and clinicians from over 30 countries, with the U.S. well represented. For sure, you will hear the latest in the fields of drug discovery, drug development, drug utilization, clinical trials and mental health economics. As an added value, there will be an optional day and a half psychopharmacology update course preceding the meeting at a minimal cost for those registered for the full Congress. Don't miss it!

Continuing Medical Education

This activity has been approved for PRA AMA credit. July 9-13, 2006



CINP 2006 • 1608 17th Avenue South • Nashville, TN USA 37212 Phone: (1) 615-322-2006 • Fax: (1) 615-385-3174 • Email: cinp2006@cinp.org

Scientific Secretariat: cinp2006.scientific@cinp.org • Oakley Ray, Executive Director Oray@cinp.org Brian Leonard, President • Herbert Meltzer, National Organizing Chair

Pictured above: Frank Gehry Millennium Park Band Shell, Chicago, Illinois

://doi.org/10.1017/S109285290001422X Published online by Cambridge University Press

Volume 11 -

CNS SPECTRUMS

The International Journal of Neuropsychiatric Medicine

EDITOR'S LETTER

165 Making a Diagnosis When One is Not Apparent: Bridging the Gap Between Somatic Patient and Frustrated Physician Jack M. Gorman, MD

INTRODUCTION

187 "Mirror, Mirror..." Whose Explanation is the Fairest? Evolving Notions of Somatization and Idiopathic Physical Symptoms

Charles C. Engel, MD, MPH, Uniformed Services University of the Health Science

ORIGINAL RESEARCH

179 A Discrimination Based on Autogenous Versus Reactive Obsessions in Obsessive-Compulsive Disorder and Related Clinical Manifestations

> Lutfullah Besiroglu, MD, Yüzüncü Yıl University School of Medicine; Mehmet Yucel Agargun, MD, Yüzüncü Yıl University School of Medicine; Ozgur Ozbebit, MD, Yüzüncü Yıl University School of Medicine; and Adem Aydin, MD, Yüzüncü Yıl University School of Medicine

REVIEW ARTICLES

190 The Potentially Somatizing Effect of Clinical Consultation

Peter Salmon, DPhil, Royal Liverpool University Hospital

201 Idiopathic Physical Symptoms: A Common Manifestation of Psychiatric Disorders in Primary Care

Javier I. Escobar MD, University of Medicine and Dentistry of New Jersey—Robert Wood Johnson Medical School; Alejandro Interian, PhD, University of Medicine and Dentistry of New Jersey—Robert Wood Johnson Medical School; Angelica Díaz-Martínez, PhD, University of Medicine and Dentistry of New Jersey—Robert Wood Johnson Medical School; and Michael Gara, PhD, University of Medicine and Dentistry of New Jersey—Robert Wood Johnson Medical School

212 Antidepressants and Cognitive-Behavioral Therapy for Symptom Syndromes

Jeffrey L. Jackson, MD, MPH, Uniformed Services University of the Health Science; Patrick G. O'Malley, MD, MPH, Walter Reed Army Medical Center; and Kurt Kroenke, MD, Indiana University

225 Explanatory and Pragmatic Perspectives Regarding Idiopathic Physical Symptoms and Related Syndromes

Charles C. Engel, MD, MPH, F. Edward Hebert School of Medicine of the Uniformed Services University of the Health Science

MISSION

CNS Spectrums' editorial mission is to address relevant neuropsychiatric topics, including the prevalence of comorbid diseases among patients, and original research and reports that emphasize the profound diagnostic and physiologic connections made within the neurologic and psychiatric fields. The journal's goal is to serve as a resource to psychiatrists and neurologists seeking to understand and treat disturbances of cognition, emotion, and behavior as a direct consequence of central nervous system disease, illness, or trauma.

Now indicated for Panic disorder

panic attacks persistent fear and worry anticipatory anxiety Break the cycle with EFFEXOR XR'

IMPORTANT TREATMENT CONSIDERATIONS

Suicidality in Children and Adolescents

Antidepressants increased the risk of suicidal thinking and behavior (suicidality) in short-term studies in children and adolescents with Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of EFFEXOR XR or any other antidepressant in a child or adolescent must balance this risk with the clinical need. Patients who are started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. EFFEXOR XR is not approved for use in pediatric patients.

EFFEXOR XR is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs). Adult and pediatric patients taking antidepressants can experience worsening of their depression and/or the emergence of suicidality. Patients should be observed closely for clinical worsening and suicidality, especially at the beginning of drug therapy, or at the time of increases or decreases in dose. Anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania have been reported and may represent precursors to emerging suicidality. Stopping or modifying therapy should be considered especially when symptoms are severe, abrupt in onset, or not part of presenting symptoms.

- Treatment with venlafaxine is associated with sustained increases in blood pressure (BP) in some patients. Postmarketing cases of elevated BP requiring immediate treatment have been reported. Pre-existing hypertension should be controlled. Regular BP monitoring is recommended.
- Abrupt discontinuation or dose reduction has been associated with discontinuation symptoms. Patients should be counseled on possible discontinuation symptoms and monitored while discontinuing the drug; the dose should be tapered gradually.
- The most common adverse events reported in EFFEXOR XR shortterm placebo-controlled depression, generalized anxiety disorder (GAD), social anxiety disorder (SAD), and/or panic disorder (PD) trials (incidence ≥10% and ≥2x that of placebo) were anorexia, asthenia, constipation, dizziness, dry mouth, ejaculation problems, impotence, insomnia, nausea, nervousness, somnolence, and sweating.

Reference: 1. Data on file, Wyeth Pharmaceuticals Inc.



The change they deserve.

Please see brief summary of Prescribing Information on adjacent pages.

Wyeth % 2005, Wyeth Pharmaceuticals Inc., Philadelphia, PA 19101 116525-01 December 2005



BRIEF SUMMARY. See package insert for full prescribing information.

Suicidality in Children and Adolescents

Antidepressants increased the risk of suicidal thinking and behavior (suicidality) in short-term studies in children and adolescents with Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of EFFEXOR XR or any other antidepressant in a child or adolescent must balance this risk with the clinical need. Patients who are started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. EFFEXOR XR is not approved for use in pediatric patients. (See Warnings and Precautions: Pediatric Use.)

Pooled analyses of short-term (4 to 16 weeks) placebo-controlled trials of 9 antidepressant drugs (SSRIs and others) in children and adolescents with Major Depressive Disorder (MDD), obsessivecompulsive disorder (OCD), or other psychiatric disorders (a total of 24 trials involving over 4,400 patients) have revealed a greater risk of adverse events representing suicidal thinking or behavior (suicidality) during the first few months of treatment in those receiving antidepressants. The average risk of such events in patients receiving antidepressants was 4%, twice the placebo risk of 2%. No suicides ourred in these trials.

(subcidainty) during the first few months of treatment in those receiving antidepressants. The average trisk of such events in patients receiving antidepressants was 4%, twice the placebo risk of 2%. No subcides occurred in these trials.
CONTRAINDICATIONS: Hypersensitivity to venilataxine hydrochioride or to any excipients in the formulation. Concomitant use in patients taking monoamine oxidase inhibbors (MAOL), WANNINGS: Clinical Worsening on Suicide Risk.— Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and/or the emergence of suicidality in cartain patients. Antidepressant increased the risk of suicidal them and one standing concern that antidepressants may have a role in inducing worsening of the pression and the emergence of suicidality in cartain patients. Antidepressant increased the risk of suicidal tinuing and behavior (suicidality) in short-term studies in childrait patients being treated with antidepressants for any indication should be observed indication patients being treated with antidepressants for any excipient the suicidality risk in pediatric patients extends to longer-term use, i.e., beyond several months. It is also unknown whether the suicidality risk in pediatric patients as does changes, either increases or decreases. Adults with MDD or comorbid depression in the setting of other psychiatric lillines being treated with antidepressants for any bary, or at times of dose changes, either increases or decreases. Anteky, tagitation, panic attacks, insomnia, inribality, hostify, aggressiveness, impulsivity, akathisia (osychomotor restlessness), hypomania, and mania have been reported in adult and peterssion is besistent, workes, or altowal and on symptoms and either the worse either increases or subjectidatic, Althougg a causal link between the emergence of suicidation, in patients whose depression is persistent workes, or altowal and and barba of ecusions should be given to changing the theresthere spreasing suicid immediate treatment have been reported. Pre-existing hypertension should be controlled. Regular monitoring of BP is recommended. For patients experiencing sustained increase in BP, consider either dose reduction or discontinuation. **PRECAUTIONS: General**—*Discontinuation of Treatment with Effexor XR*. Abrupt discontinuation or dose reduction of venlafaxine at various doses is associated with new symptoms, the frequency of which increased with increased dose level and longer duration of treatment. Symptoms include agilation, anorexia, anxiety, confusion, coordination impaired, diarrhea, dizziness, dry mouth, dysphoric mood, emotional lability, fasciculation, fatigue, headaches, hypomania, insomnia, irritability, lethargy, nausea, nervousness, nightmares, seizures, sensory disturbances (e.g., paresthesias such as electric shock sensations), somnolence, sweating, tinnitus, tremor, vertigo, and vomiting. Monitor patients when discontinuing treatment. A gradual reduction in the dose rather than abrupt cessation is recommended. If inflerable symptoms poccur following a decrease in the dose promo discontinuing in or freatment consider sensativity, sufficience, sweating, trimine, tendo, and voltating, monitoring, monitoring, and the discontinuity is the sense of the dose or upon discontinuity of the dose at a more gradual rate. Insomnia and Nervousness: Treatment-emergent insomnia and nervousness have been reported. In Phase 3 trials, insomnia led to drug discontinuation in 1% of both depressed patients and Paric Disorder (PD) patients and in 3% of both Generalized Anxiety Disorder (GAD) and Social Anxiety Disorder (GAD) patients. Nervousness is a trials, insomnia led to drug discontinuition in 1% of both depressed patients, in 2% of GAD patients, and in 3% of both Generalized Anxiety Disorder (GAD) and Social Anxiety Disorder (GAD) patients and in 3% of both Generalized Anxiety Disorder (GAD) and Social Anxiety Disorder (GAD) patients and in 3% of both Generalized Anxiety Disorder (GAD) and Social Anxiety Disorder (GAD) patients. Nervousness led to drug discontinuation in 0.9% of depressed patients, in 2% of GAD patients, and in 3% of SAD and BAD strings. The sentence is a string in the sentence in the sentence is a string in the sen Children and adolescents in a 6-month study had increases in weight less than expected based on data from age- and sex-matched peers. The difference between observed and expected weight gain was larger for children -12 years oil than for adolescents >12 years oil. Changes in Meight Peotleartic Patients: In 8-week GAD studies, Effexor XR patients aged 6-17 grew an average of 0.3 cm (n=142), while placebo patients grew an average of 1.0 cm (n=132). P=0.041. This difference in height increase was most notable in patients aged a vareage of 1.0 cm (n=132). P=0.041. This difference in height increase was most notable in patients (=12, in 8-week MDD studies, Effexor XR patients grew an average of 0.8 cm (n=146), while placebo patients (=12, in 8-week MDD studies, Effexor XR patients grew an average of 0.8 cm (n=146), while placebo patients (=12, in 8-week MDD studies, Effexor XR patients grew an average of 0.8 cm (n=146), while placebo patients (=12, in 8-week MDD studies, Effexor XR patients grew an average of 0.8 cm (n=146), while placebo patients (=12, in 8-week MDD studies, Effexor XR patients grew an average of 0.8 cm (n=146), while placebo patients (=12, in 8-week MDD studies, Effexor XR (=147,) in a 6-month study, children and adolescents had height increases less than expected based on data from age- and sex-matched peers. The difference between observed and expected growth rates was larger for children <12 years old than for adolescents >12 years old. Changes in Appetitic 40(%) patients in MDD studies. The discontinuation rate for anorexia was 1.0% in MDD studies. Treatment-emergent anorexia was more commonly reported for Effexor XR (8%) than placebo (=2%) patients in GAD studies. Treatment-emergent anorexia was more commonly reported for Effexor XR (20%) than placebo (=2%) patients. AD studies. Treatment-anorexia was more commonly reported for Effexor XR (20%) than placebo (=2%) patients in ADD studies. The discontinuation rate for anorexia was 0.4% for up to 12 weeks in GAD studies. Treat

Decreased appetite was seen in pediatric patients receiving Effexor XR. In GAD and MDD trials, 10% of Effexor XR patients aged 6-17 for up to 8 weeks and 3% of placebo patients had treatment-emergent anorexia. None of the patients receiving Effexor XR discontinue for anorexia or weight loss. *Activation of Mania/Hypomania*: Mania or hypomatrenia and/or the syndrome of inappropriate antidiuretic hormone secretion (SIADH) may occur with venlafaxine. Consider this in patients who are volume-depleted, elderly, or taking diuretics. *Mypinatise*: Myponatrenia and/or the syndrome of inappropriate antidiuretic hormone secretion (SIADH) may occur with venlafaxine. Consider this in patients who are volume-depleted, elderly, or taking diuretics. *Mypinatise*: Mydriasis: haybeen reported; no.13% of venlafaxine patients. Use cautiously in patients with a history of solzures. Discontinue in any patient who develops seizures. *Abnormal Bleeding*: Abnormal bleeding (most commonly ecchymosis) has been reported. Io.3% of venlafaxine patients and 0.0% of placebo patients treated for at least 3 months in trials. Consider measurement of serum cholesterol levels during long-term treatment. *Use In Patients With Concornitat Illness*: Use Effexor XR catiously in patients with a elsen reported in cilical studies. Exercise cation in patients whose underlying medical conditions might be compromised by increases in heart rate. In patients with renal impairment or cirrhosis of the liver, the clearances of venlafaxine and its active metabolites were decreased, prolonging the elimination half-lives. A lower dose may be necessary, use with cation in such patients. Information for Patients — Precibers or other health professional should inform their st, their families, and their caregivers about the benefits and risks associated with treatment with Effexor XR and should counsel them in its appropriate use. A patient Medication Guide Boot boot server is available to recrease in for the reation of use aboutsymptoms on a day-to-day basis, since o Decreased appetite was seen in pediatric patients receiving Effexor XR. In GAD and MDD trials, 10% of Effexor recommended. **Drug Interactions**—**Alcoha** A single does of ethanol had no effect on the pharmacokinetic (PK) of ventifications of 0-desmethylivenitations (DV), and ventification of the optic optications with intellifies to patients with pre-existing hypertinesion or hepatic dystunction, and the eldowit. **Diazepann** A single does of diazepan did not appear to affect the PK of ethier ventification eV of Ventification eV of the technic **Diazepann** A single does of diazepan did not appear to affect the PK of ethier ventification eV of ventification eV of the pro-period technic technic biolication of the single dystunction, and the eldowith of account of helpoperiod instantion harl-life was unchanged. Lifethum A single does of lifthum di not appear to affect the PK of ether ventification is not helpoperiod was unchanged. Lifethum A single does of lifthum di not appear to affect the PK of ether ventification is not helpoperiod was unchanged. Lifethum A single does of lifthum di not appear to affect the PK of ether ventification is not helpoperiod was unchanged. Lifethum A single does of lifthum di not appear to affect the PK of ether ventification is not appear to affect the PK of lifthum. Tange Highly Bound to Plasma Proteins: Ventification is not NUX ventification is the ether proteins and the site of veschlaterin likking abnormal docrased links, end evening. Commonly Observed Adverse Events in coordination all provides and the second sec

Wyeth® © 2005, Wyeth Pharmaceuticals Inc., Philadelphia, PA 19101

Volume 11

CNS SPECTRUN

Number 3

The International Journal of Neuropsychiatric Medicine

CLINICAL UPDATES IN NEUROPSYCHIATRY

News From the Field of 166 Neuroscience

- Retrospective Study Highlights Benefits of SSRIs in PTSD
- Risks of Aspirin in Intracerebral Hemorrhage May Not be as High as Expected
- Comorbid Major Depression May Affect Progression of Alzheimer's Disease

CASE REPORT

172 Pramipexole: Augmentation in the Treatment of Depressive Symptoms

Sanjay Gupta, MD, University of Buffalo School of Medicine and Biomedical Sciences; Jennifer L. Vincent, BA, Cattaraugus County Continuing Day Treatment Program; and Bradford Frank, MD, MPH, MBA, University of Buffalo School of Medicine and Biomedical Sciences

ROUNDTABLE MONOGRAPH SUPPLEMENT

CME

Incorporating Pharmacogenetics Into Clinical Practice: Reality of a New Tool in Psychiatry

> Moderator: David A. Mrazek, MD Discussants: Jordan W. Smoller, MD, ScD, and Jose de Leon, MD

CME QUIZ

The quiz is CME-accredited by Mount Sinai School of Medicine 233 for 3.0 credit hours.

GENERAL INFORMATION

- **Call for Papers** 170
- 171 Author Guidelines

Founded in 1996, CNS Spectrums is indexed in Index Medicus and is available on MEDLINE under the citation CNS Spectr. CNS Spectrums is also distributed to all CINP members and is accredited for international CME by EACIC.

CNS Spectrums (ISSN 1092-8529) is published monthly by MBL Communications, Inc. 333 Hudson Street, 7th Floor, New York, NY 10013.

One-year subscription rates: domestic \$120; foreign \$195; in-training \$85. For subscriptions: Tel: 212-328-0800; Fax: 212-328-0600; Web: www.cnsspectrums.com. Single issues: \$15 – E-mail jg@mblcommunications.com

For editorial inquiries, please fax us at 212-328-0600 or E-mail José R. Ralat at jrr@mblcommunications.com. For bulk reprint purchases, please contact Christopher Naccari at cdn@mblcommunications.com.

Postmaster: Send address changes to CNS Spectrums c/o MMS, Inc., 185 Hansen Court, Suite 110, Wood Dale, IL 60191-1150.

Opinions and views expressed by authors are their own and do not necessarily reflect the views of the publisher, MBL Communications, Inc., or the editorial advisory board.

Advertisements in CNS Spectrums are accepted on the basis of adherence to ethical medical standards, but acceptance does not imply endorsement by CNS Spectrums or the publisher.

CNS Spectrums is a registered trademark of CNS Spectrums, LLC, New York, NY. Permission to reproduce articles in whole or part must be obtained in writing from the publisher.

BPA member since July 2005.



This month's issue of CNS Spectrums, as well as a host of educational resources, enduring materials, and archived issues, is available at www.cnsspectrums.com.

162

For effective lithium treatment, effectively delivered...

Start with or switch to **LITHOBID**[®]

Because lithium is a narrow therapeutic index drug, careful dose titration and patient monitoring are required for its safe and effective use. To ensure that your patients with bipolar disorder receive the LITHOBID brand that you have prescribed, just write **NO SUBSTITUTIONS (NS)** or **DISPENSE AS WRITTEN (DAW)**, depending on the laws in your state.

Dispense As Written



Lithium toxicity is closely related to serum lithium levels, and can occur at doses close to therapeutic levels. Facilities for prompt and accurate serum lithium determinations should be available before initiating therapy. Treatment must be individualized according to serum concentrations and clinical response.



LITHOBID® Slow-Release Tablets 300 mg

Dispense As Written

Please see brief summary of full Prescribing Information on adjacent page. Published online by Cambridge University Press ©2005 JDS Pharmaceuticals LLC April 2005 LB05-04 www.ldspharma.com

LITHOBID® (lithium carbonate)

Slow-Release Tablets 300mg

R, only

BRIEF SUMMARY: Consult the full prescribing information for complete product information.

WARNING

Lithium toxicity is closely related to serum lithium levels, and can occur at doses close to therapeutic levels. Facilities for mt and accurate serum lithium determination should be available before initiating therapy.

INDICATIONS

Lithium is indicated in the treatment of manic episodes of manic-depressive illness. Maintenance therapy prevents or diminishes the intensity of subsequent episodes in those manic-depressive patients with a history of mania. Typical symptoms: of mania include pressure of speech, motor

hyperactivity, reduced need for sleep, flight of ideas, grandiosity, elation, poor judgment, aggressiveness, and possibly hostility. When given to a patient experiencing a manic episode, lithium may produce a normalization of symptomatology within 1 to 3 weeks.

WARNINGS

Lithium should generally not be given to patients with significant renal or cardiovascular disease, severe debilitation, dehydration, sodium depletion, and to patients receiving diuretics, or angiotensin converting enzyme (ACE) inhibitors, since the risk of lithium toxicity is very high in such patients. If the psychiatric indication is life threatening, and if such a patient fails to respond to other measures, lithium treatment may be undertaken with extreme caution, including daily serum lithium determinations and adjustment to the usually low doses ordinarily tolerated by these individuals. In such instances, hospitalization is a

necessity. Chronic lithium therapy may be associated with diminution of renal concentrating ability, occasionally presenting as nephrogenic diabetes insipidus, with polyuria and polydipsia. Such patients should be carefully managed to avoid dehydration with resulting lithium retention and toxicity This condition is usually reversible when lithium is discontinued. Morphologic changes with glomerular and interstitial fibrosis and nephron

atrophy have been reported in patients on chronic lithium therapy. Morphologic changes have also been seen in manic-depressive patients never exposed to lithium. The relationship between renal function and morphologic changes and their association with lithium therapy have not been established.

Kidney function should be assessed prior to and during lithium therapy putine urinalysis and other tests may be used to evaluate tubula function (e.g., urine specific gravity or osmolality following a period of water deprivation, or 24-hour urine volume) and giomerular function (e.g., serum creatinine or creatinine clearance). During lithium therapy, progressive or sudden changes in renal function, even within the normal range, indicate the need for re-evaluation of treatment.

An encephalopathic syndrome (characterized by weakness, lethargy fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN and FBS) has occurred in a few patients treated with lithium plus a neuroleptic, most notably haloperidol. In some instances, the syndrome was followed by irreversible brain damage. Because of possible causal relationship between these events and the concomitant administration of lithium and neuroleptic drugs, patients receiving such combined therapy or patients with organic brain syndrome or other CNS impairment should be monitored closely for early evidence of neurologic toxicity and treatment discontinued promptly if such signs appear. This encephalopathic syndrome may be similar to or the same as Neuroleptic Malignant Syndrome (NMS). Lithium toxicity is closely related to serum lithium concentrations and can

occur at doses close to the therapeutic concentrations. Outpatients and their families should be warned that the patient must discontinue lithium therapy and contact his physician if such clinical signs of lithium toxicity as diarrhea, vomiting, tremor, mild ataxia, drowsiness, or muscular weakness occur.

Lithium may prolong the effects of neuromuscular blocking agents. Therefore, neuromuscular blocking agents should be given with caution to patients receiving lithium.

Usage in Pregnancy

Adverse effects on nidation in rats, embryo viability in mice, and metabolism in vitro of rat testis and human spermatozoa have been attributed to lithium, as have teratogenicity in submammalian species and cleft palate in mice.

In humans, lithium may cause fetal harm when administered to a pregnant woman. Data from lithium birth registries suggest an increase in cardiac and other anomalies especially Ebstein's anomaly. If this drug is used in women of childbearing potential, or during pregnancy, or if a patient becomes pregnant while taking this drug, the patient should be apprised by their physician of the potential hazard to the fetus.

Usage in Nursing Mothers

Lithium is excreted in human milk. Nursing should not be undertaken during lithium therapy except in rare and unusual circumstances where, in the view of the physician, the potential benefits to the mother outweigh possible hazard to the infant or neonate. Signs and symptoms of lithium toxicity such as hypertonia, hypothermia, cyanosis and ECG changes have been reported in some infants and neonates.

Pediatric Use

Safety and effectiveness in pediatric patients under 12 years of age have not been determined; its use in these patients is not recommende

There has been a report of transient syndrome of acute dystonia and hyperreflexia occurring in a 15 kg pediatric patient who ingested 300 mg of lithium carbonate.

PRECAUTIONS

The ability to tolerate lithium is greater during the acute manic phase and decreases when marks symptoms subside. The distribution space of lithium approximates that of total body water.

Lithium is primarily excreted in urine with insignificant excretion in feces. Renal excretion of lithium is proportional to its plasma concentration. The elimination half-life of lithium is approximately 24 hours. Lithium decreases sodium reabsorption by the renal tubules which could lead to sodium depletion. Therefore, it is essential for the patient to maintain a normal diet, including salt, and an adequate fluid intake (2500-3500 mL) at least during the initial stabilization period. Decreased tolerance to lithium has been reported to ensue from protracted sweating or diarrhea and, if such occur, supplemental fluid and salt should be administered under careful medical supervision and lithium intake reduced or suspended until the condition is resolved.

In addition to sweating and diarrhea, concomitant infection with elevated temperatures may also necessitate a temporary reduction or cessation of medication

Previously existing thyroid disorders do not necessarily constitute a contraindication to lithium treatment. Where hypothyroidism preexists, careful monitoring of thyroid function during lithium stabilization and maintenance allows for correction of changing thyroid parameters and/ or adjustment of lithium doses, if any. If hypothyroidism occurs during lithium stabilization and maintenance, supplemental thyroid treatment may be used

In general, the concomitant use of diuretics or angiotensin convertienzyme (ACE) inhibitors with lithium carbonate should be avoided. In those cases where concomitant use is necessary, extreme caution is advised since sodium loss from these d rugs may reduce the renal clearance of lithium resulting in increased serum lithium concentrations with the risk of lithium toxicity. When such combinations are used, the lithium dosage may need to be decreased, and more frequent monitoring of lithium serum concentrations recommended (see WARNINGS for additional caution information).

Concomitant administration of carbamazenine and lithium may increase the risk of neurotoxic side effects.

The following drugs can lower serum lithium concentrations by increasing urinary lithium excretion: acetazolamide, urea, xanthine preparations and alkalinizing agents such as sodium bicarbonate.

Concomitant extended use of iodide preparations, especially potassium iodide, with lithium may produce hypothyroidism. Concurrent use of calcium channel blocking agents with lithium may

increase the risk of neurotoxicity in the form of ataxia, tremors, nausea, vomiting, diarrhea and/or tinnitus.

Concurrent use of metronidazole with lithium may provoke lithium toxicity due to reduced renal clearance. Patients receiving such combined therapy should be monitored closely

Concurrent use of fluoxetine with lithium has resulted in bothincreased and decreased serum lithium concentrations. Patients receiving such

combined therapy should be monitored closely. Nonsteroidal anti-inflammatory drugs (NSAIDS): Lithium levels should be closely monitored when patients initiate or discontinue NSAID use.

In some cases, iithium toxicity has resulted from interactions between an NSAID and lithium. Indomethacin and piroxicam have been reported to increasesignificantly steady-state plasma lithium concentrations. There is also evidence that other nonsteroidal anti-inflammatory agents, including the selective cyclooxygenase-2 (COX-2) inhibitors, have the same effect. In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with celecoxib 200 mg BID as compared to subjects receiving lithium alone.

Lithium may impair mental and/or physical abilities. Patients should be cautioned about activities requiring alertness (e.g., operating vehicles or machinery).

Usage in Pregnancy Pregnancy Category D. (see WARNINGS)

Usage in Nursing Mothers

Because of the potential for serious adverse reactions in nursing infants and neonates from lithium, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother (see WARNINGS). Pediatric Use

Safety and effectiv

ness in pediatric patients below the age of 12 have not been established (see WARNINGS). Geriatric Use

Clinical studies of LITHOBID® Tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting

the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other therapy. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

ADVERSE REACTIONS

The occurrence and severity of adverse reactions are generally directly related to serum lithium concentrations and to individual patient sensitivity to lithium. They generally occur more frequently and with greater severity at higher concentrations.

dverse reactions may be encountered at serum lithium concentrations below 1.5

mEq/L. Mild to moderate adverse reactions may occur at concentrations from 1.5-2.5 mEq/L, and moderate to severe reactions may be seen at concentrations from 2.0 mEq/L and above.

Fine hand tremor, polyuria and mild thirst may occur during initial therapy for the acute manic phase and may persist throughout treatment. Transient and mild nausea and general discomfort may also appear during the first few days of lithium administration. These side effects usually subside with continued treatment or with a

temporary reduction or cessation of dosage. If persistent, a cessation of lithium therapy may be required. Diarrhea, vomiting, drowsiness, muscular weakness and lack of coordination may be early signs of lithium intoxication, and can occur at lithium concentrations below 2.0 mEq/L. At higher concentrations, giddiness, ataxia, blurred vision, tinnitus and a large output of dilute urine may be seen. Serum lithium concentrations above 3.0 mEq/L may produce a complex clinical picture involving multiple organs and organ systems. Serum lithium concentrations should not be permitted to exceed 2.0 mEq/L during the acute treatment phase The following reactions have been reported and appear to be related to serum lithium concentrations, including concentrations within the therapeutic range:

Central Nervous System: tremor, muscle hyperirritability (fasciculations, twitching, clonic movements of whole limbs), hypertonicity, ataxia, choreoathetotic movements, hyperactive deep tendon reflex, extrapyramidal symptoms including acute dystonia, cogwheel rigidity, blackout spells, epileptiform seizures, slurred speech, dizziness, vertigo, downbeat nystagmus, incontinence of urine or feces, somnolence, advintbear hysiaginus, incultinence of unite or leces, somolence, psychomotor retardation, restenses, confusion, stupor, coma, tongue movements, tics, tinnitus, hallucinations, poor memory, slowed intellectual functioning, startled response, worsening of organic Train syndromes. Cases of Pseudotumor Cerebri (increased intracranial pressure and papilledema) have been reported with lithium use. If undetected, this ndition may result in enlargement of the blind spot, constriction of visual fields and eventual blindness due to optic atrophy. Lithium should be discontinued, if clinically possible, if this syndrome occurs.

Cardiovascular: cardiac arrhythmia, hypotension, peripheral circulatory collapse, bradycardia, sinus node dysfunction with severe bradycardia (which may result in syncope); Gastrointestinal: anorexia, nausea, vomiting, diarrhea, gastritis, salivary gland swelling, abdominal pain, excessive salivation, flatuience, indigestion; Genitourinary: glycosuria, decreased creatinine clearance, albuminuria, oliguria, and symptoms of nephrogenic diabetes insipidus including polyuria, thirst and polydipsia; Dermatologic: drying and thinning of hair, alopecia, anesthesia of skin, acne, chronic folliculitis, xerosis cutis, psoriasis or its exacerbation, generalized pruritus with or without rash, cutaneous ulcers, angioedema; Autonomic Nervous System: blurred vision, dry mouth, impotence sexual dysfunction; Thyroid Abnormalities; euthyroid goiter and/or hypothyroidism (including myxedema) accompanied by lower T3 and T4. 131lodine uptake may be elevated. Paradoxically, rare cases of hyperthyroidism have been reported. EEG Changes: diffuse slowing widening of frequency spectrum, potentiation and disorganization of background rhythm.

background nryim. EKG Changes: reversible flattening, isoelectricity or inversion of T-waves. Miscellaneous: Fatigue, lethargy, transient scotomata, exophihalmos, dehydration, weight loss, leucocytosis, headache, transient-hyperglycemia,hypercalcemia, hyper-parathyroidism, albuminuria, excessive weight gain, edematous swelling of ankles or ankles or the second wrists, metallic taste, dysgeusia/taste distortion, salty taste, thirst, swollen lips, tightness in chest, swollen and/or painful joints, fever, polyarthraigia, and dental caries. Some reports of nephrogenic diabetes insipidus, hyperparathyroidism

and hypo-thyroidism which persist after lithium discontinuation have been received

A few reports have been received of the development of painful discoloration of fingers and toes and coldness of the extremities within one day of starting lithium treatment. The mechanism through which these symptoms (resembling Raynaud's Syndrome) developed is not known. Recovery followed discontinuance

OVERDOSAGE

The toxic concentrations for lithium (1.5 mEq/L) are close to the therapeutic concentrations (0.6-1.2 mEg/L). It is therefore important that patients and their families be cautioned to watch for early toxic symptoms and to discontinue the drug and inform the physician should they occur. (Toxic symptoms are listed in detail under ADVERSE REACTIONS).

Treatment: No specific antidote for lithium poisoning is known. Treatment is supportive. Early symptoms of lithium toxicity can usually be treated by reduction or cessation of dosage of the drug and resumption of the treatment at a lower dose after 24 to 48 hours. In severe cases of lithium poisoning, the first and foremost goal of treatment consists of elimination of this ion from the patient.

Treatment is essentially the same as that used in barbiturate poisoning: 1) gastric lavage, 2) correction of fluid and electrolyte imbalance and, 3) regulation of kidney functioning. Urea, mannitol, and aminophylline all produce significant increases in lithium excretion. Hemodialysis is an effective and rapid means of removing the ion from the severely toxic patient. However, patient recovery may be slow.

Infection prophylaxis, regular chest X-rays, and preservation of adequate respiration are essential.



NOC 68968-4492-1 (Bottle of 100)

Manufactured By: Solvay Pharmaceuticals, Inc., Marietta, GA 30062 For: JDS Pharmaceuticals, LLC, New York, NY 10168 Rev 2/05